Mel

Stocks & Shares DYOR, MYOD and HAVE FUN!

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK Impact report highlights potential scale of @TVLithium's Billingham refinery:

🔹£2.1bn UK economic contribution over 25 years
🔹~1,700 jobs supported
🔹To run on 100% renewable electricity

£11 of economic value created for every £1 invested.

RNS: https://t.co/V7sJ44Can0

[Avacta @avacta]

Avacta today released updated Phase 1a/1b and pharmacokinetics, safety, toxicity and preliminary efficacy data with faridoxorubicin at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. https://t.co/yQ7kjJpSbP #AVCT

[Richard Hughes @hughesy0707]

In my personal view 2026 will be a defining point for #AVCT and ultimately for long term cancer patients.

Thanks to all shareholders and stakeholders for their support.

[Richard Hughes @hughesy0707]

Delighted to be appointed as chairman of #AVCT

My core priority is to ensure the value of preCISION is exploited to its fullest, for the benefit of all shareholders.

I am more than confident we have the team and the intellectual property to enable this.

[Blencowe Resources Plc (LON:BRES) @BlencoweRes]

#BRES Beehive recap:110 shallow holes delivered thick intercepts from surface incl. 30.09m @ 10.78% TGC & 31.4m @ 9.46% TGC.

Deep holes confirm #Graphite to ~100m. Open for step-outs (N/W/S).

Modelling now very advanced toward maiden Beehive JORC.

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK | @TVLithium advances project development

🔹Independent cost validation confirms robust FEED estimate
🔹Among lowest-cost lithium projects globally
🔹Site, infrastructure & environmental workstreams progressing

Execution momentum building

RNS: https://t.co/ks7Xhbgyxg

[Myles McNulty @MylesMcNulty]

Look across the pond at UK-listed @avacta $AVCT #AVCT.

Targeted oncology.

Its pre|CISION platform can be used to modify practically any anti-cancer small molecule or biologic, into a peptide-drug conjugate.

These PDCs can be used to target around 85% of all types of cancer cases.

Two drugs in the clinic. One to kick off a Pivotal Phase 2/3 trial this summer; the second drug having just commenced a Phase 1 trial.

The uber bull case is that pre|CISION PDCs eventually displace the large majority of the existing and anticipated ADC market. PDCs...

- are significantly more targeted than ADCs;
- are much lower cost (as don't require an expensive biologic such as a mAb);
- have broader applicability (almost tumour agnostic - see 85% fig above);
- have broader versatility (the Avacta scientists can modify practically any warhead with pre|CISION);
- have superior tumour penetration and tissue diffusion, owing to their smaller size.

In fact, it is difficult to point out a single major advantage that the existing class of ADCs enjoys over Avacta's PDCs.

If the second drug in clinic - AVA6103, a modified version of the all-powerful warhead, exatecan - replicates the published pre-clinical data (22/24 complete responses in various animals models - a CR rate of 92%), it has the real potential to blow Enhertu (and even Keytruda) out the water.

By virtue of Avacta's UK listing, this opportunity exists. The UK investment community is a shadow of what it once was - it lacks depth, breadth, and many of its participants do not possess the intellectual curiosity and/or risk tolerance for pre-revenue / lossmaking entities.

Were Avacta listed on NASDAQ right now, I would suggest it'd be valued at at least 10x its current mkt cap of $363m.

[Avacta @avacta]

We are thrilled to share a major milestone for our pipeline: the first patient has been treated in the FOCUS-01 Phase 1 trial of AVA6103 (FAP-Exd), our sustained-release pre|CISION® exatecan peptide drug conjugate. https://t.co/sGGbU7vQHZ #AVCT #FOCUSontheWIN

[Avacta @avacta]

Avacta CEO Chris Coughlin joined an expert panel this week in Lisbon at #BIOEuropeSpring to discuss the latest innovation and opportunity shaping the oncology landscape, from precision medicine and immunotherapies to novel modalities and combination treatments. #AVCT

[Myles McNulty @MylesMcNulty]

A historic period for @avacta approaches.

In the next 2 weeks or so, the first patients will be dosed in the Phase 1 trial for AVA6103 - 'the Beast', as it's referred to inside the halls of #AVCT.

The company last month detailed how AVA6103 enjoys a number of key advantages over the world's best-selling antibody-drug conjugate, Enhertu. The pre-clinical models for 6103 in the public domain reveal a complete response rate of >90%.

The Phase 1 trial is initially focusing on four indications: pancreatic, cervical, gastric and small cell lung cancer. If all is going well in the first few months, it would not surprise to see the trial expanded to include colorectal (given how impressive the pre-clinical results were in this indication), and possibly others.

Analysts have Enhertu achieving peak sales of $10bn to $12bn in a few years' time. What has inexplicably not been covered by equity analysts yet is that 6103 could have a total addressable market of 5 times, possibly 10 times, that of Enhertu. And, due to its significantly superior targeting, it should simultaneously demonstrate significantly higher efficacy and reduced side effects, relative to Enhertu.

In the meantime, Avacta's (current) lead asset, AVA6000, has continued to generate superb data in its Phase 1b trial, notably for salivary gland cancer - for which it is likely to at least double the historic benchmark PFS. SGC is a $250m per annum opportunity. A registrational Phase 2 trial for 6000 targeting this indication should kick off this summer (subject to funding).

Management would never state this publicly, but I suspect they consider the probability of AVA6000 receiving marketing approval for SGC to be ~90% now.

Does the company now joint venture it, so that a larger partner can help fund it through Phase 2 before sales can commence? Or license it out, for a free carry and then royalties (possibly with a small upfront cash sum)? Or could AVA6000 (for SGC only) just be sold in full, for a large cash sum?

The last option would probably be the worst-value (for existing shareholders) in the long-term, as a result of missing out on a share of 5+ years of >$200m per annum, high-margin sales. On the other hand, it would minimize equity dilution for the foreseeable, and ensure that Avacta can keep 6103, 100%-owned through to at least the start of Phase 2.

Moreover, one could argue that if 6103 performs in clinic as management thinks / hopes(!) it will, then it's highly likely that the company would be acquired before it can enjoy any royalties / profit share from 6000 SGC sales.

In any event, I am certain that the company now has an array of attractive options before it, to fund operations and growth.

To think that this year - in the next 6-9 months - we will know if pre|CISION is likely going to disrupt the global oncology market, and ultimately displace the budding ADC class (not to mention, the very large majority of conventional chemotherapy).

This company could become a national treasure. All the information and data is in the open for everyone to peruse, and realize this.

As I have highlighted previously, the international peer group for precision oncology has demonstrated that 100x returns from Avacta's current mkt cap of £300m are entirely possible, within a relatively short timeframe (2-3 years).

I am looking forward to truly frenzied buying here in the not-too-distant.

[Blencowe Resources Plc (LON:BRES) @BlencoweRes]

#BRES Maiden Iyan JORC Resource

🔹16.9 Mt @ 6.0% TGC (Inferred)
🔹Total JORC Mineral Resources increase 66% to 43.0 Mt

Iyan confirmed as a near-surface extension of Northern Syncline system, adding scale ahead of Beehive results and further JORC growth.

📰: https://t.co/bizpduLWp9

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK Europe racing to localise battery materials.

@TVLithium designed to supply 25,000tpa lithium hydroxide, expandable to 100,000tpa.

🔹>94% recovery, capex/opex among lowest in Europe
🔹FEED complete; advancing FID, financing & development

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK | @TVLithium advances on-site lithium recovery & recycled supply

🔹Up to ~$16M p.a. via improved lithium yield
🔹Framework in place for up to 50kt recycled feedstock
Stronger economics. Higher recovery.

📰 RNS: https://t.co/VjkZwtLSSN

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK | @TVLithium completes FEED study for its Teesside refinery

🔹$65.9M EBITDA p.a.
🔹Among lowest capital intensities in Europe (SC Insights)
🔹40% of capacity under binding offtake

Now advancing financing and FID

RNS: https://t.co/RVnaEeg1Uo

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK | @TVLithium signs binding offtake agreement with Glencore

🔹5-year deal for up to 50,000t of battery-grade LiOH
🔹First deliveries aligned with 2028 production
🔹Major milestone ahead of FID, validating TVL’s model & market position

RNS: https://t.co/RCIdRewVWS

[Blencowe Resources Plc (LON:BRES) @BlencoweRes]

#BRES Exceptional first deep hole at newly identified Iyan deposit confirms continuous high-grade graphite from surface to ~100m

Major new zone not in current JORC, strengthening Orom-Cross’ potential as a multi-decade supply source. 5 more deep holes + 186 assays pending

Read More👉https://t.co/a96jpXgeEw

[Blencowe Resources Plc (LON:BRES) @BlencoweRes]

🎙️#BRES CEO Mike on @VOXmarkets

🔹DFS delivered: >US$1bn NPV & 96% IRR
🔹JORC Reserves up 47%, reinforcing long-term scale
🔹Downstream purification a major value driver
🔹Further growth expected from Iyan & Beehive

Next stop: 🇺🇸 USA for high-level #CriticalMinerals meetings

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK Following the UK’s updated #CriticalMinerals Strategy, @TVLithium CEO Vikki Jeckell sets out how TVL aligns with the Government’s 2035 vision.

📌Train 1 can meet 50% of the new 50,000 tpa domestic #Lithium target.

Read our full response:
https://t.co/85YdqLcwGB

[Blencowe Resources Plc (LON:BRES) @BlencoweRes]

#BRES “Downstream processing in-country makes a huge difference to our NPV - turning lower-value concentrate into high-value purified #Graphite.”

🔹DFS targeting end Nov (Q4)

🎥@that_stocks_guy

[Alkemy Capital Investments Plc (LON:ALK) @AlkemyCapital]

#ALK | @TVLithium update

🔹FEED study advancing with CapEx & OpEx reductions
🔹ABGSC leading US$245m project-level financing

CEO now fully focused on delivery ahead of Q1 2026 FID.

Read more: https://t.co/WR0klURZar